뒤로
Castle Biosciences Inc(CSTL) 가격
CSTL 주가 차트
CSTL 수입
Castle Biosciences Inc
$42.84
-0.46%
$-0.19
종가: Jan 27, 16:00:00 GMT-5
$42.87
0.07%
$0.02
애프터마켓: Jan 27, 18:00:19 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-03
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
CSTL의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Castle Biosciences Inc CSTL의 지난 분기 매출 실적은 어땠나요?
Castle Biosciences Inc의 매출 추정치는 얼마인가요?
Castle Biosciences Inc의 수익 품질 점수는 얼마인가요?
Castle Biosciences Inc는 언제 수익을 보고하나요?
Castle Biosciences Inc의 예상 수익은 얼마인가요?
Castle Biosciences Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$43.04
시가
$42.98
일일 범위
$42.39 - $43.22
52주 범위
$14.59 - $44.28
거래량
353.2K
평균 거래량
431.1K
EPS(TTM)
-0.45
배당수익률
--
시가총액
$1.2B
CSTL란 무엇인가요?
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.